Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Perspective Therapeutics, Inc. (CATX : AMEX)

• Company Description    Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash. Number of Employees: 166

• Price / Volume Information    Yesterday's Closing Price: $3.98 Daily Weekly Monthly 20 Day Moving Average: 1,420,578 shares Shares Outstanding: 114.05 (millions) Market Capitalization: $453.90 (millions) Beta: 1.75 52 Week High: $6.16 52 Week Low: $1.96 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.75% -16.06% 12 Week -21.34% -27.29% Year To Date 44.73% 29.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2401 ELLIOTT AVENUE SUITE 320 - SEATTLE,WA 98121 USA ph: 206-676-0900 fax: 509-267-3670 ir@perspectivetherapeutics.com http://www.perspectivetherapeutics.com

• General Corporate Information    Officers Johan Thijs Spoor - Chief Executive Officer and Director Lori A. Woods - Chairperson Joel Sendek - Chief Financial Officer Jonathan Hunt - Chief Accounting Officer Heidi Henson - Director Peer Information Perspective Therapeutics, Inc. (GSAC) Perspective Therapeutics, Inc. (CASIF) Perspective Therapeutics, Inc. (ALCD.) Perspective Therapeutics, Inc. (OMNN) Perspective Therapeutics, Inc. (CGPI.) Perspective Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 46489V302 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 114.05 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.75 Market Capitalization: $453.90 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.27 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.31 Price/Cash Flow: - Price / Sales: 734.47 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -77.78% vs. Previous Quarter: 76.74% ROE 03/31/26 - -42.33 12/31/25 - -41.79 09/30/25 - -40.03 ROA 03/31/26 - -35.05 12/31/25 - -34.76 09/30/25 - -33.99 Current Ratio 03/31/26 - 8.75 12/31/25 - 5.17 09/30/25 - 8.66 Quick Ratio 03/31/26 - 8.75 12/31/25 - 5.17 09/30/25 - 8.66 Operating Margin 03/31/26 - -18,194.18 12/31/25 - -11,813.12 09/30/25 - -10,084.75 Net Margin 03/31/26 - -17,982.69 12/31/25 - -11,665.27 09/30/25 - -9,841.86 Pre-Tax Margin 03/31/26 - -18,194.18 12/31/25 - -11,813.12 09/30/25 - -10,084.75 Book Value 03/31/26 - 3.05 12/31/25 - 2.79 09/30/25 - 3.26 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.01 09/30/25 - 0.01 Debt-to-Capital 03/31/26 - 0.45 12/31/25 - 0.75 09/30/25 - 0.65

Powered by Zacks Investment Research ©